Section 265.20 - Possession and Sale of a Self-Defense Spray
391-S - Restricted access to retail sale of dextromethorphan, commonly known as “dxm"
Mental Health Law 9.46 requires mental health professionals to report to their local director of community services ("DCS") or his/her designees when, in their reasonable professional judgment, one of their patients is "likely to engage in conduct that would result in serious harm to self or others." The reporting requirement extends to "mental health professionals," defined in the law as four professions – physicians (including psychiatrists), psychologists, registered nurses, or licensed clinical social workers.
Time allowed employees to vote.
Vision Screening Tests FAQ
Publication 52, Hazardous, Restricted, and Perishable Mail > 4 Restricted Matter > 45 Other Restricted Materials > 453 Controlled Substances and Drugs
The following acts and the causing thereof are prohibited:
June 20, 2013 - The FDA approved the use of Plan B One-Step (levonorgestrel) as a nonprescription product for all women of child-bearing potential. This action complies with the April 5, 2013 order of the United States District Court in New York to make levonorgestrel-containing emergency contraceptives available as an over-the-counter (OTC) product without age or point-of-sale restrictions.
Article 137, Pharmacy
8. Any person to sell or distribute any instrument or article, or any recipe, drug or medicine for the prevention of conception to a minor under the age of sixteen years; the sale or distribution of such to a person other than a minor under the age of sixteen years is authorized only by a licensed pharmacist but the advertisement or display of said articles, within or without the premises of such pharmacy is hereby prohibited; [Injunction - Injunctive relief against enforcement of subd. 8 of this section which prohibited distribution of contraceptives to persons under the age of 16, which prohibited distribution of contraceptives to any other persons by persons other than pharmacists, and which prohibited any display or advertisement of contraceptives was appropriate. Population Services Intern. V. Wilson, D.C.N.Y. 1975, 398 F. Supp. 321, 97 S.Ct. 2010, 431 U.S. 678, 52 L.Ed.2d 675.]
5-c. (a) No health care plan shall implement an adverse reimbursement change to a contract with a health care professional that is otherwise permitted by the contract, unless, prior to the effective date of the change, the health care plan gives the health care professional with whom the health care plan has directly contracted and who is impacted by the adverse reimbursement change, at least ninety days written notice of the change. If the contracting health care professional objects to the change that is the subject of the notice by the health care plan, the health care professional may, within thirty days of the date of the notice, give written notice to the health care plan to terminate his or her contract with the health care plan effective upon the implementation date of the adverse reimbursement change. For the purposes of this subdivision, the term “adverse reimbursement change” shall mean a proposed change that could reasonably be expected to have a material adverse impact on the aggregate level of payment to a health care professional, and the term “health care professional” shall mean a health care professional licensed, registered or certified pursuant to title eight of the education law. The notice provisions required by this subdivision shall not apply where: (i) such change is otherwise required by law, regulation or applicable regulatory authority, or is required as a result of changes in fee schedules, reimbursement methodology or payment policies established by a government agency or by the American Medical Association's current procedural terminology (CPT) codes, reporting guidelines and conventions; or (ii) such change is expressly provided for under the terms of the contract by the inclusion of or reference to a specific fee or fee schedule, reimbursement methodology or payment policy indexing mechanism.
The MAC Appeals Law, Public Health Law §280-a, took effect March 10, 2016. It maps out a process to appeal and resolve disparities within multi-source drug pricing (MACs) between pharmacies and pharmacy benefit managers.
The law defines a pharmacy benefit manager (PBM) and requires a reasonable process to appeal and resolve disputes regarding MAC pricing.
USP General Chapter <800> provides standards for safe handling of hazardous drugs to minimize the risk of exposure to healthcare personnel, patients and the environment.
Executive Order No. 202.10
No pharmacist shall dispense hydroxychloroquine or chloroquine except when written as prescribed for an FDA-approved indication; or as part of a state approved clinical trial related to COVID-19 for a patient who has tested positive for COVID-19, with such test result documented as part of the prescription. No other experimental or prophylactic use shall be permitted, and any permitted prescription is limited to one fourteen day prescription with no refills.
Executive Order No. 202.24
Section 6801 of the Education Law, to the extent necessary to authorize licensed pharmacists to order COVID-19 tests, approved by the Food and Drug Administration (FDA), to detect SARS-CoV-2 or its antibodies, and to administer COVID-19 tests subject to certificate of waiver requirements pursuant to the federal clinical laboratory improvement act of nineteen hundred eighty-eight, in patients suspected of a COVID-19 infection, or suspected of having recovered from COVID-19 infection, subject to completion of appropriate training developed by the Department of Health;